CLINICAL TRIALS PROFILE FOR EMBEDA
✉ Email this page to a colleague
All Clinical Trials for EMBEDA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00415597 ↗ | Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain | Completed | Pfizer | Phase 3 | 2006-12-01 | Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months. |
| NCT00420992 ↗ | A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee | Completed | Pfizer | Phase 3 | 2006-12-01 | The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period. |
| NCT01100437 ↗ | Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients | Terminated | Pfizer | Phase 4 | 2010-04-01 | This study will evaluate whether crushed EMBEDA capsules induce clinical opiate withdrawal signs and symptoms in opioid-dependent patients with chronic non-cancer pain who are stabilized on EMBEDA. |
| NCT01179191 ↗ | Conversion to Embeda With Rescue Trial | Terminated | Pfizer | Phase 4 | 2010-08-01 | The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion. |
| NCT01380093 ↗ | Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users | Completed | Pfizer | Phase 1 | 2011-02-01 | The primary purpose of this study is to determine the abuse potential of EMBEDA compared to controlled release morphine when crushed and taken orally by non-dependent recreational opioid users; secondary purposes include to determine the abuse potential of crushed EMBEDA relative to placebo and and to compare the pharmacokinetics and safety of crushed EMBEDA with crushed controlled-release morphine and crushed placebo. |
| NCT01595867 ↗ | Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo | Completed | Pfizer | Phase 1 | 2010-08-01 | This was a single-dose, randomized, double-blind, placebo-controlled, 3 way crossover study designed to evaluate the relative abuse potential of crushed EMBEDA® compared to morphine sulfate CR tablets and placebo in healthy male and female, non-dependent, recreational opioid users. An appropriate dose of morphine sulfate CR (i.e., 30 mg, 60 or 90 mg) was to be selected during Part A of the study (Dose Selection Phase). Each subject participated in the study for up to (approximately) 16 weeks and was confined in the clinic for a total of up to 12 nights. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for EMBEDA
Condition Name
Clinical Trial Locations for EMBEDA
Trials by Country
Clinical Trial Progress for EMBEDA
Clinical Trial Phase
Clinical Trial Sponsors for EMBEDA
Sponsor Name
